novel

AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) DeficiencyAlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency

AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infantsClinical estimates for SP-B deficiency…

6 months ago
SoldierStrong to Support Veterans with Novel Immersive Healthcare TechnologySoldierStrong to Support Veterans with Novel Immersive Healthcare Technology

SoldierStrong to Support Veterans with Novel Immersive Healthcare Technology

November 14, 2024 09:00 ET | Source: SoldierStrong SoldierStrong to support the physical rehabilitation of the men and women of…

6 months ago
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingCompass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and…

6 months ago
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Companys Novel Business Model as Key to Sustainable Success through Patient AffordabilityTevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Companys Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Companys Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending.Approximately…

7 months ago
Show previous Posts